James Wooldridge has joined Checkmate Pharmaceuticals as chief medical officer, the same position he held most recently at Aeglea BioTherapeutics. Wooldridge’s experience also includes more than a decade at Eli Lilly (NYSE: [[ticker:LLY]]), where he held several positions in cancer drug development. Cambridge, MA-based Checkmate is developing a type of cancer drug called an oligonucleotide. The company’s lead drug candidate, CMP-001, is in early-stage testing.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
